Association of Antidementia Drugs and Mortality in Community-Dwelling Frail Older Patients With Dementia: The Role of Mortality Risk Assessment
| Autor: | Pilotto, A., Polidori, M. C., Veronese, N., Panza, F., Arboretti Giancristofaro, R., Daragjati, J., Carrozzo, E., Prete, C., Gallina, P., Padovani, A., Maggi, S., Cruz-Jentoft, A., Durando, M., Ferrucci, L., Fratiglioni, L., Mattace-Raso, F., Paccalin, M., Ruppe, G., Schulz, R. -J., Topinkova, E., Trifirò, G., Welmer, A. -K., Multidimensional Prognostic Index (MPI)_Age Project Investigators |
|---|---|
| Přispěvatelé: | Internal Medicine, Medical Informatics, Pilotto, A., Polidori, M.C., Veronese, N., Panza, F., Arboretti Giancristofaro, R., Daragjati, J., Carrozzo, E., Prete, C., Gallina, P., Padovani, A., Maggi, S., Cruz-Jentoft, A., Durando, M., Ferrucci, L., Fratiglioni, L., Mattace-Raso, F., Paccalin, M., Ruppe, G., Schulz, R.-J., Topinkova, E., Trifirò, G., Welmer, A.-K., Multidimensional Prognostic Index (MPI)_Age Project Investigators |
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Male
Gerontology medicine.medical_specialty Frail Elderly Multidimensional assessment antidementia drug Lower risk Comprehensive geriatric assessment Risk Assessment Article 03 medical and health sciences 0302 clinical medicine Older patients SDG 3 - Good Health and Well-being Risk Factors antidementia drugs comprehensive geriatric assessment Dementia frailty mortality multidimensional prognostic index (MPI) Nursing (all)2901 Nursing (miscellaneous) Health Policy Geriatrics and Gerontology Internal medicine medicine Humans 030212 general & internal medicine Multidimensional prognostic index (MPI) Mortality Geriatric Assessment General Nursing Aged Retrospective Studies Aged 80 and over Frailty business.industry Hazard ratio General Medicine medicine.disease Survival Analysis Confidence interval Antidementia drugs Female Independent Living Nursing homes business Risk assessment 030217 neurology & neurosurgery |
| Zdroj: | Journal of the American Medical Directors Association, 19(2), 162-168. Elsevier Inc. |
| ISSN: | 1525-8610 |
| Popis: | Objective: To evaluate whether treatment with antidementia drugs is associated with reduced mortality in older patients with different mortality risk at baseline. Design: Retrospective. Setting: Community-dwelling. Participants: A total of 6818 older people who underwent a Standardized Multidimensional Assessment Schedule for Adults and Aged Persons (SVaMA) evaluation to determine accessibility to homecare services or nursing home admission from 2005 to 2013 in the Padova Health District, Italy were included. Measurements: Mortality risk at baseline was calculated by the Multidimensional Prognostic Index (MPI), based on information collected with the SVaMA. Participants were categorized to have mild (MPI-SVaMA-1), moderate (MPI-SVaMA-2), and high (MPI-SVaMA-3) mortality risk. Propensity score-adjusted hazard ratios (HR) of 2-year mortality were calculated according to antidementia drug treatment. Results: Patients treated with antidementia drugs had a significant lower risk of death than untreated patients (HR 0.82; 95% confidence interval [CI] 0.73–0.92 and 0.56; 95% CI 0.49–0.65 for patients treated less than 2 years and more than 2 years treatment, respectively). After dividing patients according to their MPI-SVaMA grade, antidementia treatment was significantly associated with reduced mortality in the MPI-SVaMA-1 mild (HR 0.71; 95% CI 0.54–0.92) and MPI-SVaMA-2 moderate risk (HR 0.61; 95% CI 0.40–0.91, matched sample), but not in the MPI-SVaMA-3 high risk of death. Conclusions: This large community-dwelling patient study suggests that antidementia drugs might contribute to increased survival in older adults with dementia with lower mortality risk. © 2017 AMDA – The Society for Post-Acute and Long-Term Care Medicine |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|